NCT07600177RecruitingPhase 4
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 20 May 2026
Brief summary (registry, in English)
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 7 May 2026
- Start date
- 5 May 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Oregon Health and Science University
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT07600177
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 40
- From 5 May 2026 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis).
- Documented history of current obstructive coronary artery disease (\> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.
Lab values
- History of LVEF \<30%.
Other
- Severe aortic stenosis or sub-aortic obstruction
- Paroxysmal atrial fibrillation (AF) with documented episode within 3 months.
- Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.
Who the study is looking for
- Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.
- Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.
- Patient willing to consent for the study and undergo the study procedures.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Luke's Hospital - Mid America Heart Institute Coordinator of this site? Confirm its status | Kansas City | United States | Not yet recruiting |
| Oregon Health Science University Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.